Genentech at outperform by RBC

Genentech, Inc. was reiterated at outperform, average risk, with a $91 price target by RBC Capital Markets analyst Jason Kantor on expectations of above-consensus earnings per share of $0.52. Strength in the quarter should come mostly from Herceptin and Rituxan with possible weakness in Avastin and Lucentis a wild card, according to Kantor. RBC lowered its third-quarter earnings per share estimate to $0.52 from $0.54. Shares of the South San Francisco, Calif.-based biotherapeutic company were up $1.30, or 1.58%, at $83.70. (NYSE: DNA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.